CeriBell (NASDAQ:CBLL) Stock: Insider Joseph Michael Taylor Sells 10,200 Shares

CeriBell, Inc. (NASDAQ:CBLL) Director Joseph Taylor sold 10,200 shares of the stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $27.22, for a total transaction of $277,644.00. Following the transaction, the director directly owned 38,278 shares of the company’s stock, valued at $1,041,927.16. This represents a 21.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Joseph Michael Taylor also recently made the following trade(s):

• On Thursday, August 13th, Joseph Taylor sold 13,095 shares of CeriBell stock. The shares were sold at an average price of $23.40, for a total transaction of $306,423.00.

CeriBell Price Performance

Shares of CBLL opened at $27.80 on Thursday. The company has a current ratio of 8.18, a quick ratio of 7.79 and a debt-to-equity ratio of 0.17. The stock’s 50 day moving average is $25.46 and its two-hundred day moving average is $21.00. CeriBell, Inc. has a twelve month low of $12.36 and a twelve month high of $28.89. The firm has a market capitalization of $1.08 billion, a PE ratio of -14.33 and a beta of 0.86.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). The business had revenue of $29.34 million for the quarter, compared to analysts’ expectations of $29.18 million. CeriBell had a negative return on equity of 52.59% and a negative net margin of 67.96%. Research analysts anticipate that CeriBell, Inc. will post -2.05 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Canaccord Genuity Group upped their price objective on CeriBell from $26.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. BTIG Research reissued a “buy” rating on shares of CeriBell in a report on Wednesday, November 4th. Barclays upgraded shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $29.00 price target on shares of CeriBell in a research note on Thursday, September 3rd. Finally, TD Cowen increased their price target on shares of CeriBell from $29.00 to $33.00 and gave the company a “buy” rating in a report on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $31.25.

Institutional Investors Weigh In On CeriBell

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE acquired a new stake in shares of CeriBell in the 2nd quarter worth approximately $4,619,000. TimesSquare Capital Management LLC purchased a new position in CeriBell in the 2nd quarter valued at approximately $15,182,000. BlackRock Inc. purchased a new position in CeriBell in the 2nd quarter valued at approximately $37,657,000. Bank of New York Mellon Corp acquired a new position in CeriBell during the second quarter worth $17,437,000. Finally, Deutsche Bank AG acquired a new position in CeriBell during the second quarter worth $1,742,000.

CeriBell Company Profile

Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.